Andere talen Benitec Biopharma Inc.

Aandelen

BNTC

US08205P2092

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8,869 ^USD	+12,26%		+27,79%	+174,57%

18/04	Benitec Biopharma Inc. Rapporteert positieve tussentijdse klinische onderzoeksgegevens voor de eerste OPMD proefpersoon behandeld met BB-301 in Fase 1b/2a Studie	CI
13/02	Benitec Biopharma Inc. rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Benitec Biopharma to Participate in the Citizens JMP Life Science Conference	01/05
Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	22/04
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	18/04
Top Midday Gainers	18/04
Top Premarket Gainers	18/04
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18/04
Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18/04
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million	18/04
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024	09/04
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update	13/02
Benitec Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02
Benitec Biopharma Doses First Participant in Trial of Treatment for Oculopharyngeal Muscular Dystrophy	30/11
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	30/11
Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	30/11
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference	17/11
Earnings Flash (BNTC) BENITEC BIOPHARMA Posts Q1 Revenue $0M	13/11
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update	13/11
Benitec Biopharma Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	13/11
Certain Common Stock of Benitec Biopharma Inc. are subject to a Lock-Up Agreement Ending on 6-NOV-2023.	06/11
Benitec Biopharma : Material Event - Form 8-K	29-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Benitec Biopharma Inc.

Aandelen

BNTC

US08205P2092

Andere talen

Filters